Skip to main content

AgomAb Therapeutics NV

corporate_fare Company Profile

AgomAb Therapeutics NV

AGMB·NASDAQ·Life Sciences·CIK 0002020932

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company that develops new therapies for immunology and inflammatory diseases, specifically targeting chronic fibrotic conditions where current treatments are lacking. The company's pipeline includes Ontunisertib (AGMB-129), an oral, gastrointestinal-restricted small molecule that inhibits ALK5 or TGFßR1. This therapy is currently in Phase 2a clinical trials for the treatment of Fibrostenosing Crohn's disease. Another product, AGMB-447, is an inhaled small molecule inhibitor of ALK5 or TGFßR1, which is in Phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis. AgomAb Therapeutics NV also develops AGMB-101, a HGF-mimetic monoclonal antibody. This antibody works by stimulating the MET receptor and has shown antifibrotic and regenerative activity in preclinical studies. The company was incorporated in 2017 and is based in Antwerp, Belgium.

AgomAb Therapeutics NV (NASDAQ:AGMB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for AGMB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-13, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for AGMB spans 6-K, 20-F, SCHEDULE 13D, 424B4.

Recent high-impact activity:

  • Agomab Doses First Patient in Global Phase 2b NOV-ERA Study of Ontunisertib in Fibrostenosing Crohn's Disease
  • Agomab's Ontunisertib Shows 3% Event Rate in Crohn's Fibrosis Extension Study
  • Agomab's Lung Drug Shows >50% Target Reduction in Phase 1, Paving Way for Phase 2
  • Agomab Reports Positive Phase 1 Data for AGMB-447 in IPF; Phase 2 INSPIRIA Study to Start H2 2026
  • Agomab Reports Half-Year 2026 Financials, Confirms Outlook, and Extends Cash Runway into 2029

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$62.55M
Diluted EPS
-$143.22
Op. Cash Flow
-$51.74M
Operating Income
-$59.27M
Cash & Equivalents
$86.42M
Debt / Equity
0.00×
Shares Outstanding
25K sh
Source: 20-F · filed 2026-04-23 · accession 0001104659-26-047872

Short Interest & Short Volume

7.44 days to cover

FINRA reported short interest of 920,851 shares in AGMB as of the October 30, 2026 settlement, a 2.2% decrease from the prior period — about 7.4 days to cover at its recent average daily volume. On November 20, 2026, 36.7% of AGMB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)920,851 shares as of October 30, 2026
Change vs prior period▼ 2.2%
Days to cover7.44 at avg daily volume of 123,797
Daily short volume (FINRA facilities)36.7% of 72,436 shares on November 20, 2026
5-day average short volume19.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

AGMB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →
$5.45
52-week range · as of 2026-10-13 $5.45 – $17.82
Market cap
$268.4M
Volume
189K (0.8× avg)
3-mo avg 240.3K
Live data · 2026-11-22 04:57 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AGMB - Latest Insights

AGMB
Oct 13, 2026, 5:18 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.81
Real-time Price: $5.45 info
Change: -$3.36 (-38%) info
Market Cap: $268.401M info
AGMB
Oct 01, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.10
Real-time Price: $5.45 info
Change: -$5.65 (-51%) info
Market Cap: $268.401M info
AGMB
Sep 14, 2026, 4:48 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $12.28
Real-time Price: $5.45 info
Change: -$6.83 (-56%) info
Market Cap: $268.401M info
AGMB
Sep 14, 2026, 4:14 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $12.28
Real-time Price: $5.45 info
Change: -$6.83 (-56%) info
Market Cap: $268.401M info
AGMB
Aug 06, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.50
Real-time Price: $5.45 info
Change: -$8.05 (-60%) info
Market Cap: $268.401M info
AGMB
Aug 06, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $13.50
Real-time Price: $5.45 info
Change: -$8.05 (-60%) info
Market Cap: $268.401M info
AGMB
Jun 23, 2026, 5:14 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $11.94
Real-time Price: $5.45 info
Change: -$6.49 (-54%) info
Market Cap: $268.401M info
AGMB
Jun 23, 2026, 4:13 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $11.94
Real-time Price: $5.45 info
Change: -$6.49 (-54%) info
Market Cap: $268.401M info
AGMB
Apr 23, 2026, 6:14 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $10.70
Real-time Price: $5.45 info
Change: -$5.25 (-49%) info
Market Cap: $268.401M info
AGMB
Apr 23, 2026, 5:17 PM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $10.70
Real-time Price: $5.45 info
Change: -$5.25 (-49%) info
Market Cap: $268.401M info
AGMB
Mar 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.70
Real-time Price: $5.45 info
Change: -$7.25 (-57%) info
Market Cap: $268.401M info
AGMB
Mar 05, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $14.21
Real-time Price: $5.45 info
Change: -$8.76 (-62%) info
Market Cap: $268.401M info
AGMB
Feb 17, 2026, 7:00 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $15.44
Real-time Price: $5.45 info
Change: -$9.99 (-65%) info
Market Cap: $268.401M info
AGMB
Feb 09, 2026, 4:18 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $18.10
Real-time Price: $5.45 info
Change: -$12.65 (-70%) info
Market Cap: $268.401M info
AGMB
Feb 06, 2026, 4:15 PM EST
Filing Type: 424B4
Importance Score:
9
Price at Filing: $15.43
Real-time Price: $5.45 info
Change: -$9.98 (-65%) info
Market Cap: $268.401M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets